DEERFIELD, Ill., May 19, 2017 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc., a wholly-ownedsubsidiary of Takeda Pharmaceutical Company Limited, will be one of the companies to participate in the first-ever Innovation Zone, during the American Psychiatric Association (APA) 2017 Annual Meeting in San Diego,
Takeda will provide APA conference attendees with the opportunity to learn more about their current technology partners, patient education initiatives and applications to help patients. The company will also host a panel discussion featuring technology innovators, who will share insights on research, digital advancements in mental health and examples of multi-stakeholder collaboration.
For a list of Innovation Zone activities featuring Takeda, see below.
Sunday, May 21
Monday, May 22
Tuesday, May 23
Please visit the APA conference web site for a complete list of activities.
About the American Psychiatric Association Mental Health Innovation Zone
To address the ever-changing landscape in technology in relation to mental health services, the American Psychiatric Association is hosting the Mental Health Innovation Zone as part of the 2017 Annual Meeting experience. This new featured experience at the Annual Meeting will allow attendees to become part of the next wave of technology enhancements and implementations in the mental health profession. The Mental Health Innovation Zone will open Sunday, May 21, until Tuesday, May 23, 2017 in the exhibit hall of the San Diego Convention center and will feature presentations spanning from Virtual and Augmented Reality to outcomes, entrepreneurship and enterprise.
Social media: #MHIZ
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology, central nervous system and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.
For more information, visit http://www.takeda.com/news
About Takeda in the U.S.
Takeda Pharmaceuticals U.S.A., Inc. is the U.S. commercial organization of Takeda Pharmaceutical Company Limited. Takeda has a strong commitment to the U.S. with more than 5,000 employees, a significant R&D presence, Oncology and Vaccine headquarters and manufacturing capabilities.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/takeda-announces-american-psychiatric-association-apa-innovation-zone-activities-300460643.html
SOURCE Takeda Pharmaceuticals
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All